The Motley Fool
02 Nov 2026, 11:45 UTC · 4h ago
Should You Invest $1,000 in BridgeBio Pharma Right Now?
Impact · against what's priced in
BridgeBio is approaching a significant pipeline inflection point with three PDUFA dates through May 2027. The most immediate catalyst is the November 27 PDUFA for BBP-418, which follows positive phase 3 results and could expand the company's commercial portfolio to three approved therapies.
- BBIO+0.60
No priced-in read yet
- In context
The November 27 PDUFA date for BBP-418 follows positive phase 3 trial results and represents a potential shift from two approved therapies to three. While other milestones like oral infigratinib (Feb 4) and encaleret (May 8) are identified, BBP-418 provides the most immediate near-term catalyst.
Read from the article alone
